- Rosuvastatin is more effective at lowering LDL-C and small dense LDL compared to atorvastatin. A meta-analysis of 28 randomized trials found rosuvastatin significantly reduced sdLDL levels compared to atorvastatin. - In high-risk patients, rosuvastatin more effectively reduced the risk of cardiovascular events compared to atorvastatin, as seen in the CORALL study. Rosuvastatin also reduced cardiovascular risk in patients with impaired fasting glucose in the JUPITER trial. - Rosuvastatin has shown favorable safety in terms of liver and muscle effects compared to other statins. The risk of ALT or CK elevation is lower with rosuvastatin compared to other statins, especially

1. Insights In The Recent Guidelines of
Management of Diabetic
Dyslipidemic Patients
BY
ASHRAF OKBA
PROF.OF INTERNAL MEDICINE
AIN SHAMS UNIVERSITY
Cairo -Egypt

2. 1- http://www.diabetesprevention.pitt.edu/index.php/for-the-public/diabetes-and-related-conditions/cardiovascular-disease/last access 25/5/2015
2-J Am Coll Cardiol. 2007 May 15;49(19):1918-23. Epub 2007 Apr 30.
Noninvasive screening for coronary atherosclerosis and silent ischemia in asymptomatic type 2 diabetic patients: is it appropriate and cost-effective?
Beller GA1.et al
Diabetes and CVD
Adults with diabetes
are 2-4 times more
likely to develop CVD
than people without
diabetes(1) Coronary artery
disease (CAD)
accounts for 65% to
80% of deaths in
diabetic patients(2)

3. East West Study: Patients with Diabetes
at Similar Risk to No Diabetes with MI
0
10
20
30
40
50
7-yearincidencerateofMI(%)
No prior MI
MI
p<0.001
p<0.001
No diabetes (n=1373) Diabetes
(n=1059)
Adapted from Haffner SM et al. N Engl J Med 1998;339:229–234

4. What types of lesions cause MI ?
Falk E, et al. Circulation. 1995;92:657-671.
100
80
60
40
20
0
14%
18%
68%
All four
studies
50%-70%<50% >70%
100
60
40
20
0
Ambrose
1988
Little
1988
Nobuyoshi
1991
Giroud
1992
Coronarystenosis(%)
Coronary stenosis severity prior to MI
80
4 www.drsarma.in

5. Years after DM Diagnosis
≤ 2 3-5 6-9 10-14 15+
15%
21%
24%
29%
48%
Harris, S et al.; Type 2 Diabetes and Associated Complications in Primary Care in
Canada: The Impact of Duration of Disease on Morbidity Load. CDA 2003.
Duration of T2DM and CVD
5

6. Duration of DM - CV Mortality
0
0.5
1
1.5
2
2.5
3
3.5
4
< 5 6 to 10 11 to 15 16 to 25 26 +
Duration of Diabetes (years)
p for trend <0.001
Cho, et al. J Am Coll Card 2002:40:954.
RelativeRisk
6

7. Kannel WB. Am Heart J. 1985;110:1100-1107.
Abbott RD et al. JAMA. 1988;260:3456-3460.
Women, Diabetes, and CHD
• Diabetic women are at high risk for CHD
• Diabetes eliminates relative cardioprotective
effect of being premenopausal
– Risk of recurrent MI in diabetic women is
three times that of nondiabetic women
• Age-adjusted mean time to recurrent MI or
fatal CHD event is 5.1 yr for diabetic women vs
8.1 yr for nondiabetic women

8.  Predisposition to thrombosis
- Atherogenic Diabetic Dyslipidemia
- Platelet hyper-aggregability
- Elevated concentrations of pro-coagulants
- Decreased concentration and activity of
antithrombotic factors
 Predisposition to attenuation of fibrinolysis
- Decreased t-PA activity
- Increased PAI-1
- Decreased concentrations of 2-antiplasmin
Imbalance Between Thrombosis and Fibrinolysis in
Subjects with Diabetes
Sobel BE. Circulation 1996;93:1613-1615.

9. ADD, Atherogenic Diabetic Dyslipidemia

10. Large LDL Small Dense LDL
Apo B
LDL-C
130 mg/dL
Fewer Particles &
Less Risk/Particle
More Particles &
More Risk/Particle
More Apo-B
Otvos JD, et al. Am J Cardiol. 2002;90:22i-29i.
TC 198 mg/dL
LDL-C 130 mg/dL
TG 90 mg/dL
HDL-C 50 mg/dL
Non–HDL-C 148 mg/dL
TC 210 mg/dL
LDL-C 130 mg/dL
TG 250 mg/dL
HDL-C 30 mg/dL
Non–HDL-C 180 mg/dL
Same LDL-C Levels, Different Cardiovascular Risk.
Lipid ProfileLipid Profile

11.  Increased susceptibility to oxidation
 Increased vascular permeability
 Conformational change in apo B
 Decreased affinity for LDL receptor
 Association with insulin resistance syndrome
 Association with high TG and low HDL
Small Dense LDL and CHD
Potential Atherogenic Mechanisms
Austin MA et al. Curr Opin Lipidol 1996;7:167-171.

12. Feingold KR et al. Arterioscler Thromb. 1992;12:1496-1502.
Lamarche B et al. Circulation. 1997;95:69-75.
Significance of Small, Dense LDL
• Low cholesterol content of LDL particles
–  particle number for given LDL-C level
• Associated with  levels of TG and LDL-C, and
 levels of HDL2
• Marker for common genetic trait associated with
 risk of coronary disease (LDL subclass pattern B)
• Possible mechanisms of  atherogenicity
– greater arterial uptake
–  uptake by macrophages
–  oxidation susceptibility

13. SMC=smooth muscle cell.
Adapted from Bierman EL. Arterioscler Thromb. 1992;12:647-656.
Potential Mechanisms of
Atherogenesis in Diabetes
• Abnormalities in apoprotein and lipoprotein particle
distribution
• Glycosylation and advanced glycation of proteins in
plasma and arterial wall
• “Glycoxidation” and oxidation
• Procoagulant state
• Insulin resistance and hyperinsulinemia
• Hormone-, growth-factor–, and cytokine-enhanced SMC
proliferation and foam cell formation

14. DM = CAD - Because
• CVD is responsible for 60 - 75% of mortality in T2DM
• CVD is 4 times more prevalent in diabetes; CADI is more
• CVD prevalence increases with age, so is T2DM
• CVD in DM is often severe, silent, poor prognosis and fatal
• Diabetes ↑ mortality, 50% pre adm / recurrent MI and ACS
• Diabetes erases the protection conferred to women
• At diagnosis of T2DM, most patients have evidence of CVD
• Abnormal Glucose tolerance is a strong CV Risk factor
14

15. Case Study
• 49-year-old white man with a history of type 2 diabetes,
obesity and hypertension.
• Non smoker
• weight fluctuating between 75 and 83 Kg.
• Most recent hemoglobin A1c of 7.4%.
• Hypertension was diagnosed 5 years ago 160/90 mmHg,
treated with Enalapril, starting at 10 mg daily and
increasing to 20 mg daily, yet his BP control has
fluctuated.

16. Case Study
• The man comes into the office today for his usual
follow-up visit for diabetes.
• Physical examination reveals an obese man with a BP
of 154/86 mmHg and a pulse of 78 bpm.
• Total cholesterol : 180 mg/dl
• LDL-c:101 mg/dl
• HDL: 35 mg/dl
• TG:220 mg/dl

18. Intensity of Statin Therapy
High-Intensity Statin Therapy Moderate-Intensity Stain
Therapy
Low-Intensity Statin Therapy
LDL–C ↓ ≥50% LDL–C ↓ 30% to <50% LDL–C ↓ <30%
Atorvastatin (40†)–80 mg
Rosuvastatin 20 (40) mg
Atorvastatin 10 (20) mg
Rosuvastatin (5) 10 mg
Simvastatin 20–40 mg‡
Pravastatin 40 (80) mg
Lovastatin 40 mg
Fluvastatin XL 80 mg
Fluvastatin 40 mg bid
Pitavastatin 2–4 mg
Simvastatin 10 mg
Pravastatin 10–20 mg
Lovastatin 20 mg
Fluvastatin 20–40 mg
Pitavastatin 1 mg
Stone NJ, et al. J Am Coll Cardiol. 2013: doi:10.1016/j.jacc.2013.11.002. Available at: http://content.onlinejacc.org/article.aspx?articleid=1770217. Accessed
November 13, 2013.
Lifestyle modification remains a critical component of ASCVD risk reduction, both prior to and in concert with the use of cholesterol
lowering drug therapies.
Statins/doses that were not tested in randomized controlled trials (RCTs) reviewed are listed in italics
†Evidence from 1 RCT only: down-titration if unable to tolerate atorvastatin 80 mg in IDEAL
‡Initiation of or titration to simvastatin 80 mg not recommended by the FDA due to the increased risk of myopathy, including rhabdomyolysis.

19. ADA 2015 guidelines Recommendations for
Statin Treatment in People with Diabetes
Age Risk factors
Recommended
statin dose*
Monitoring with
lipid panel
<40 years
None None
Annually or as
needed to monitor
for adherence
CVD risk factor(s)** Moderate or high
Overt CVD*** High
40–75 years
None Moderate
As needed to
monitor adherence
CVD risk factors High
Overt CVD High
>75 years
None Moderate
As needed to
monitor adherence
CVD risk factors Moderate or high
Overt CVD High
* In addition to lifestyle therapy.
** CVD risk factors include LDL cholesterol ≥100 mg/dL (2.6 mmol/L), high blood pressure, smoking, and
overweight and obesity.
*** Overt CVD includes those with previous cardiovascular events or acute coronary syndromes.
ADA. 8. Cardiovascular Disease and Risk Management. Diabetes Care 2015;38(suppl 1):S52, Table 8.1

20. 20

21. Focus on ASCVD Risk Reduction:
4 statin benefit groups*
21
Stone NJ, et al. J Am Coll Cardiol. 2013: doi:10.1016/j.jacc.2013.11.002. Available at:
http://content.onlinejacc.org/article.aspx?articleid=1770217. Accessed November 13, 2013.
Clinical ASCVD† LDL-C level ≥190 mg/dL
Diabetes, aged 40-75
years, with LDL-C 70-189
mg/dL
Estimated 10-year risk of
ASCVD of ≥7.5%,‡ 40-75
years of age, and with
LDL-C 70-189 mg/dL
* Moderate- or high-intensity statin therapy recommended for these 4 groups
† Clinical ASCVD defined as acute coronary syndromes, history of MI, stable or unstable angina, coronary or arterial revascularization, stroke,
transient ischemic attacks, or peripheral artery disease
‡ Estimated using Pooled Cohort Risk Assessment Equations

22. Primary Prevention
* Estimated using Pooled Cohort Risk Assessment Equations
Stone NJ, et al. J Am Coll Cardiol. 2013: doi:10.1016/j.jacc.2013.11.002. Available at: http://content.onlinejacc.org/article.aspx?articleid=1770217.
Accessed November 13, 2013.
Moderate-Intensity Statin
Patients with Diabetes and
LDL-C 70-189 mg/dL
(age 40-75 years) without
clinical ASCVD
High-Intensity Statin if ≥7.5%
estimated 10-year ASCVD risk*

23. ADA 2016 Guidelines

27. 27
Efficacy
+
SafetyCardio protection+

28. The CORALL Study
Change in LDL-C with Rosuvastatin and Atorvastatin in High-
Risk Patients
–54
–60
–50
–40
–30
–20
–10
–46
–51
–41
–46
–48
0
Rosuvastatin
Atorvastatin
6 weeks
10 mg 20 mg
12 weeks
20 mg 40 mg
18 weeks
40 mg 80 mg
n=130 n=132 n=130 n=132 n=130 n=132
***
*
*p<0.05vs ATV, **p<0.01 vs ATV
Wolffenbuttel BHR et al. J Int Med 2005; 257: 531–
539

29. Effects of rosuvastatin versus atorvastatin
on small dense low-density lipoprotein:
a meta-analysis of randomized trials.
28prospective randomized controlled clinical trials of
Rosuvastatin versus Atorvastatin therapy.
 In total, the meta-analysis included data on 7802 patients
randomized to therapy with rosuvastatin or atorvastatin.
Hisato Takagi • Masao Niwa • Yusuke Mizuno •
Hirotaka Yamamoto • Shin-nosuke Goto •
Takuya Umemoto Heart Vessels (2014) 29:287–299 DOI 10.1007/s00380-013-0358-6

30. Pooled analysis of the 28 trials:
Demonstrated a statistically significant reduction
in final sdLDL levels with rosuvastatin relative to
atorvastatin therapy ;
P-value = 0.0001.
Results

33. 33
Efficacy
+
SafetyCardio protection+

34. Cumulative Incidence of the Primary Endpoint According to
Baseline IFG Status
Impaired Fasting Glucose Normal Fasting Glucose
0 1 2 3 4
0.000.020.040.060.080.10
CumulativeIncidence
Placebo
Rosuvastatin
0 1 2 3 4
0.000.020.040.060.080.10
CumulativeIncidence
Placebo
Rosuvastatin
Follow-Up (years) Follow-Up (years)
HR 0.69 (0.49-0.98), p=0.037
JUPITER – Impaired Fasting Glucose (IFG) Subgroup Data
Pradhan A et al. Circulation 2009; 120 (Suppl): S500; Abs 1425
HR 0.51 (0.40-0.67), p<0.0001
31% 49%

37. 37
Efficacy
+
SafetyCardioprotection+

38. ALT >3 × ULN: Frequency by LDL-C reduction1,2
Persistent elevation is elevation to >3 x ULN on two successive occasions
1. Brewer H. Am J Cardiol 2003; 92(Suppl): 23K–29K
2. Davidson M. Exp Opin Drug Saf 2004; 3: 547–557
Rosuvastatin Safety – Liver Effects
0.0
0.5
1.0
1.5
2.0
2.5
3.0
20 30 40 50 60 70
LDL-C reduction (%)
Fluvastatin (20, 40, 80 mg)
Rosuvastatin (5, 10, 20, 40 mg)
Lovastatin (20, 40, 80 mg)
Atorvastatin (10, 20, 40, 80 mg)
Simvastatin (40, 80 mg)
OccurrenceofALT>3×ULN(%)

39. Rosuvastatin Safety – Muscle Effects
CK >10 x ULN: Frequency by LDL-C Reduction1,2
0.0
0.5
1.0
1.5
2.0
2.5
3.0
20 30 40 50 60 70
LDL-C reduction (%)
OccurrenceofCK>10×ULN(%)
Cerivastatin (0.2, 0.3, 0.4, 0.8 mg)
Rosuvastatin (5, 10, 20, 40 mg)
Pravastatin (20, 40 mg)
Atorvastatin (10, 20, 40, 80 mg)
Simvastatin (40, 80 mg)
1. Brewer H. Am J Cardiol 2003; 92(Suppl): 23K–29K
2. Davidson M. Exp Opin Drug Saf 2004; 3: 547–557

40. Effects of Atorvastatin and Rosuvastatin
on renal function: A meta-analysis
Author: G. Savarese et al. Publication: International Journal of Cardiology 167 (2013) 2482–2489
Design:
23 trials enrolling 29,147 participants were included in
Randomized trials about A or R treatments reporting clinical
end-points were included in the meta analysis.
Influence of both treatments on GFR and new onset proteinuria
was assessed

41. 1. Diabetic Dyslipidemia increases risk of CVD
2. ACC/AHA 2013 :Diabetic patients (age 40-75 years) and LDL
more than 70 mg/dl must receive Statins.
3. The 2015 ADA Standards of Care have been revised
to recommend when to initiate and intensify
statin therapy (high versus moderate) based on risk
profile.
4. Rosuvastatin is effective in terms of lipids profiles
including sdLDL-c and provides cardio protection with high
tolerability.
Take Home messages